Summit Therapeutics Inc. (SMMT)

Summit Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	-	-	0.71	1.81	0.86
Revenue	-	-	0.71	1.81	0.86
Revenue Growth (YoY)	-	-	-61.03%	110.35%	6.10%
Gross Profit	-	-	0.71	1.81	0.86
Selling, General & Admin	60.53	30.27	26.74	23.61	19.23
Research & Development	150.78	59.47	52	85.35	53.27
Other Operating Expenses	-0.31	-1	-14.42	-20.97	-19.31
Operating Expenses	210.99	88.74	64.33	88	53.19
Operating Income	-210.99	-88.74	-63.62	-86.19	-52.33
Interest Expense	-8.69	-16.46	-4.4	-0.24	-0.26
Interest & Investment Income	13.47	10.4	1.51	-	0
Currency Exchange Gain (Loss)	-0.1	1.03	-4.11	-2.14	0.05
Other Non Operating Income (Expenses)	-	-0.25	0.3	-0.04	0.48
EBT Excluding Unusual Items	-206.31	-94.01	-70.31	-88.6	-52.05
Asset Writedown	-	-	-8.47	-	-0.86
Pretax Income	-221.32	-614.93	-78.78	-88.6	-52.91
Income Tax Expense	-	-	-	-	-0.21
Net Income	-221.32	-614.93	-78.78	-88.6	-52.7
Net Income to Common	-221.32	-614.93	-78.78	-88.6	-52.7
Shares Outstanding (Basic)	719	620	193	92	70
Shares Outstanding (Diluted)	719	620	193	92	70
Shares Change (YoY)	15.96%	220.50%	109.60%	32.67%	111.78%
EPS (Basic)	-0.31	-0.99	-0.41	-0.96	-0.76
EPS (Diluted)	-0.31	-0.99	-0.41	-0.96	-0.76
Free Cash Flow	-142.25	-76.89	-42.21	-72.89	-48.53
Free Cash Flow Per Share	-0.20	-0.12	-0.22	-0.79	-0.70
Gross Margin	-	-	100.00%	100.00%	100.00%
Operating Margin	-	-	-9024.25%	-4764.29%	-6085.35%
Profit Margin	-	-	-11174.75%	-4897.84%	-6127.56%
Free Cash Flow Margin	-	-	-5986.67%	-4029.46%	-5643.26%
EBITDA	-210.9	-88.54	-62.36	-84.84	-50.78
D&A For EBITDA	0.09	0.2	1.26	1.35	1.55
EBIT	-210.99	-88.74	-63.62	-86.19	-52.33

Updated Feb 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q